Welcome to our dedicated page for Senestech news (Ticker: SNES), a resource for investors and traders seeking the latest updates and insights on Senestech stock.
SenesTech, Inc. develops and commercializes fertility-control products for managing animal pest populations, with current products focused on rat and mouse populations. Its product names include ContraPest, Evolve Rat, and Evolve Mouse, which are used within pest-management programs as alternatives or complements to traditional rodent-control methods.
Company news centers on Evolve commercialization, e-commerce and direct-to-consumer sales channels, Amazon marketplace management, field-study data on rodent activity, product approvals in international markets, quarterly and annual financial results, capital runway commentary, and executive leadership or board governance updates.
SenesTech (NASDAQ: SNES) reported Q1 2026 revenue of $493,000, up 2% year over year, with a company-record gross margin of 68.6%. Direct-to-consumer sales grew 42% to $194,000 and subscription revenue rose 44% to $56,000, while B2B revenue increased 57% to $298,000.
Net loss widened to $2.1 million, including $443,000 of severance and one-time legal costs. April 2026 e-commerce sales grew 163% year over year to $146,000, with subscription revenue up 198%. Michael Edell was appointed CEO, supporting the in-house Amazon and recurring revenue strategy.
SenesTech (NASDAQ: SNES) will report first quarter 2026 financial results for the period ended March 31, 2026, after market close on Tuesday, May 12, 2026. A conference call to review results is scheduled the same day at 5:00 p.m. Eastern, with a live webcast and a replay available for at least 90 days.
SenesTech (NASDAQ: SNES) appointed Michael Edell as President and Chief Executive Officer, effective May 6, 2026, and updated Board leadership to support commercial growth. Edell previously served as interim COO since October 2025 after consulting mid-2025 and led operations, Amazon sales for Evolve, and early subscription rollout.
The company said it will not refill the interim COO role and announced Matthew Szot as Board Chair while Dr. Jamie Bechtel moves to committee chair roles.
SenesTech (NASDAQ: SNES) reported 2025 results with revenue up 20% to $2.2M, driven by strong e-commerce growth and a transition to direct Amazon management. Gross margin improved to 62.5% from 54.1% and adjusted EBITDA loss narrowed to $5.3M. Cash and short-term investments totaled $8.6M, providing runway into approximately Q2 2027. Operational highlights included e-commerce revenue +88% YoY, field validation showing up to a 79% decline in rat activity at one site, regulatory approval in New Zealand, and a CEO transition with an Interim Executive Chair appointed.
SenesTech (NASDAQ: SNES) will report fourth quarter and fiscal year 2025 financial results for the period ended December 31, 2025, after market close on Thursday, March 12, 2026. A conference call to review results will be held the same day at 5:00 p.m. Eastern.
Live webcast access and a replay will be available in the Investor Relations section of the company website for at least 90 days.
SenesTech (NASDAQ: SNES) reported multi-month field results showing marked reductions in rodent activity after Evolve® deployments in two urban locations between April–August 2025 and January 2026. Tracking-plate surveys over five months showed Location A plate presence fell from 74% to 15% (79% reduction) and track density fell 88%. Location B fell from 98% to 47% presence (>50% reduction) with a 71% density decline. Results were measured via standardized tracking plates and reflect real-world urban conditions; Location A lacked pre-deployment baseline data.
SenesTech (Nasdaq: SNES) will directly manage Amazon sales of its Evolve Rat and Evolve Mouse products effective immediately, shifting from third-party sellers to in‑house e-commerce operations.
In 2025, e-commerce accounted for over 50% of revenue, with roughly half already company-managed. The change aims to increase revenue retention, improve margins, and enhance customer messaging and performance data access, with financial benefits expected to begin in Q1 and strengthen in Q2.
SenesTech (Nasdaq: SNES) announced that its fertility control product Evolve received approval for use in New Zealand from the Ministry for Primary Industries and that its exclusive distributor Evicom has received an initial stocking shipment.
Evolve is positioned as a non‑lethal, environmentally focused rodent control tool aligned with New Zealand's Predator Free 2050 initiative and the country's planned $4.5 billion investment in eradication technology.
SenesTech (NASDAQ: SNES) announced that President and CEO Joel Fruendt plans to retire and will remain in his role until a successor is found or June 30, 2026. The Board will launch a formal search and has appointed Dr. Jamie Bechtel as Interim Executive Chair to support strategic alignment and continuity during the transition.
The company said interim COO Michael Edell and CFO Tom Chesterman will continue day-to-day operations while an executive search firm assists the Board.
SenesTech (NASDAQ: SNES) announced on Nov 11, 2025 that the Belize Raptor Center, led by Sarah Mann, is an official international distributor of Evolve Rat Birth Control after receiving import and distribution approval from the Pesticides Control Board of Belize. The move aims to offer a non‑lethal, fertility‑based alternative to toxic rodenticides to protect Belize's biodiversity and reduce secondary wildlife poisonings.
The distributor partnership includes a grassroots education campaign for citizens, businesses, and officials to promote integrated pest management and phase out harmful anticoagulant and neurotoxic rodenticides.